Stock Analysis
Merck & Co., Inc. (MRK) Stock Analysis
Merck & Co., Inc. (MRK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Merck & Co., Inc. (MRK) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 71/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MRK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $149.88 |
| AIQ Score | 47/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $370.32B |
| P/E Ratio (TTM) | 119 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.54 |
| Revenue (quarter ended 2026-06-30) | $16.61B |
| Dividend Yield (TTM) | 2.24% |
| Beta | 0.21 |
| Volume | 9.01M |
| 52-week range | $82.01-$156.92 |
| RSI 14 | 59.3 |
| 50-Day SMA | $146.16 |
| 200-Day SMA | $125.49 |
| Analyst Price Target | $151.86 |
| Next Earnings | Oct 29, 2026 |
MRKMerck & Co., Inc.
Healthcare / Drug Manufacturers - General
Low Priority
Relative Laggard
Latest quote
- Momentum71
- Value27
- Quality47
- Risk resilience44
- Sentiment50
MRK Stock Analysis Summary
Merck & Co., Inc. (MRK) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 71/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MRK has AIQ Score of 47/100 with Momentum base of 71/100 and fading Value at 27/100. Wait for component alignment before adding exposure.
Momentum (71/100) leads while Value (27/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.07% stock move · MRK classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MRK Bullish or Bearish Right Now?
MRK currently has a neutral overall setup. Momentum is the strongest factor at 71/100, while Value is weakest at 27/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 71/100.
- - Price is +2.54% above its 50-day SMA.
- - Analyst target implies +1.32% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (34 vs 8).
- - Value is the current constraint at 27/100.
- - Risk Resilience is weak at 44/100.
Current Consensus
MRK's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 3 neutral, and 8 sell votes. MRK's 14-day RSI is 59.3, which places the stock in a constructive momentum range. MRK's beta is 0.21, indicating lower market sensitivity than the broad market.
What Changed in MRK?
The largest recent change in MRK is Momentum moving up by 11.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the MRK Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MRK Decision Framework
Public evidence layers, setup checks, and risk context for Merck & Co., Inc..
Merck & Co., Inc. (MRK) Stock Analysis
Merck & Co., Inc. has an AIQ Score of 47/100 in a Neutral regime. Momentum is strongest at 71/100. Beta is 0.22, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MRK is in a Neutral AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that momentum leads at 71/100 while value lags at 27/100. |
| Factor Evidence | Momentum 71/100 · Value 27/100 · Quality 47/100 · Risk 44/100 · Sentiment 50/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 71/100.
Momentum is 71/100 and RSI (14) is 59.3.
MRK is in a Neutral regime at 47/100.
Risk factor is 44/100 with beta 0.22 and annual volatility 29.63%.
Current conflict: momentum leads at 71/100 while value lags at 27/100.
MRK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MRK Fundamentals
MRK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MRK Technical Analysis
MRK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MRK Stock Catalysts
Track MRK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MRK Dividend Analysis
MRK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MRK Financial Data
MRK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MRK Risk Analysis
MRK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MRK Stock News
MRK stock news, market tone, recent headlines, and catalyst context.
MRK vs Large-Cap Pharma Peers
Current peer cohort: MRK · PFE · JNJ · ABBV · NVO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MRK Current stock | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | Current |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | MRK vs PFE |
| JNJ Johnson & Johnson | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | MRK vs JNJ |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | MRK vs ABBV |
| NVO Novo Nordisk | 67/100 | 60/100 | 56/100 | 51/100 | -0.63 | 45.71% | MRK vs NVO |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular MRK Comparisons
How MRK scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MRK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MRK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MRK Stock FAQ
What is MRK stock price today?
Merck & Co., Inc.'s current stock price is $149.88. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MRK bullish or bearish right now?
MRK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MRK's market cap?
MRK's market cap is $370.32B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MRK's current P/E ratio?
MRK's current P/E ratio is 119 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MRK's RSI?
MRK's 14-day RSI is 59.3 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MRK above its 50-day and 200-day moving averages?
MRK is 2.54% from its 50-day SMA and 19.44% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MRK's next earnings date?
MRK's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MRK pay a dividend?
MRK's dividend yield is 2.24% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.